SCHEMBL25138659

SCHEMBL25138659

O=C(COc1nc(=O)[nH]c2ccccc12)NCC1CC2CCCC(C2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ HPGD P15428 3/20 0.39
▸ GSK3A P49840 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ ROCK2 O75116 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ FAAH O00519 4/20 0.37
▸ ACHE P22303 4/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ APP P05067 1/20 0.35
▸ BCHE P06276 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25138467 0.86 KDM4E (0.39) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25138663 0.80 HPGD (0.35) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25138521 0.79 SMN1; SMN2 (0.41) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25138556 0.79 LMNA (0.33) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25138555 0.78 HPGD (0.34) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL25138470 0.78 LMNA (0.35) LMNARXFP1ALDH1A1SMN1; SMN2HPGD
SCHEMBL30361612 0.78 ALDH1A1 (0.50) LMNAALDH1A1HPGDMEN1KMT2A
SCHEMBL23900455 0.78 ALDH1A1 (0.50) LMNAALDH1A1HPGDMEN1KMT2A
SCHEMBL25138578 0.77 ALDH1A1 (0.41) LMNAALDH1A1SMN1; SMN2HPGDFAAH
SCHEMBL25138660 0.77 HPGD (0.36) LMNARXFP1ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS LMNA 4646/4885RXFP1 4748/4885ALDH1A1 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback